Barinthus Biotherapeutics (NASDAQ:BRNS) Shares Down 6.3% - Should You Sell?

Key Points

• Barinthus Biotherapeutics shares fell by 6.3%, trading at $1.30, with a significant drop in trading volume down to 39,984 shares compared to an average of 260,591.
• Weiss Ratings has issued a "sell (d-)" rating for the company, while the consensus rating remains "Hold" with a price target of $3.00.
• The company's recent earnings report showed an EPS of -$0.52, missing the expected -$0.29 by $0.23, with analysts projecting a further EPS decline for the year.

Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS - Get Free Report) shares fell 6.3% during trading on Wednesday . The company traded as low as $1.26 and last traded at $1.30. 39,984 shares traded hands during mid-day trading, a decline of 85% from the average session volume of 260,591 shares. The stock had previously closed at $1.39.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a "sell (d-)" rating on shares of Barinthus Biotherapeutics in a research report on Tuesday, October 14th. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, Barinthus Biotherapeutics currently has a consensus rating of "Hold" and a consensus price target of $3.00.

Barinthus Biotherapeutics Stock Down 6.3%

The company's 50 day moving average price is $1.25 and its 200-day moving average price is $1.10. The stock has a market cap of $53.06 million, a P/E ratio of -0.75 and a beta of -0.71.

Barinthus Biotherapeutics (NASDAQ:BRNS - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by ($0.23). Equities research analysts anticipate that Barinthus Biotherapeutics PLC Sponsored ADR will post -1.38 earnings per share for the current year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Barinthus Biotherapeutics stock. Baird Financial Group Inc. grew its position in shares of Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS - Free Report) by 108.2% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 192,461 shares of the company's stock after purchasing an additional 100,000 shares during the quarter. Baird Financial Group Inc. owned about 0.48% of Barinthus Biotherapeutics worth $179,000 as of its most recent SEC filing. Institutional investors and hedge funds own 25.20% of the company's stock.

About Barinthus Biotherapeutics

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.